{"gao_id": "GAO-21-59", "published": "2020-11-10T12:00:00Z", "released": "2020-12-10T07:00:00Z", "summary": "Healthcare providers use biopsies\u2014removing and examining cells or tissue\u2014to diagnose diseases like cancer. Labs that examine biopsies must ensure that specimens aren't misidentified or contaminated so patients can be properly diagnosed and treated. Stakeholders estimate that these errors are infrequent. In our review of studies, error rate estimates were generally around 1%, with the highest estimate at 2.3%. These errors could result, for example, from...", "title": "Clinical Labs: Studies Suggest Biopsy Specimen Misidentification and Contamination Errors Are Infrequent", "topics": ["Medicare", "Patient care", "Compliance oversight", "Cancer", "Surveys", "Errors", "Contamination", "Health Care", "Disease detection or diagnosis", "Deoxyribonucleic acid", "Clinical laboratories"], "type": "reports-testimonies", "url": "https://www.gao.gov/products/gao-21-59", "versions": [{"title": "Highlights Page (1 page)", "url": "https://www.gao.gov/assets/gao-21-59-highlights.pdf"}, {"title": "Full Report (26 pages)", "url": "https://www.gao.gov/assets/gao-21-59.pdf"}, {"title": "Accessible PDF (30 pages)", "url": "https://www.gao.gov/assets/720/710638.pdf"}]}